Research
Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67
BMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c4715 (Published 22 September 2010) Cite this as: BMJ 2010;341:c4715
Data supplement
Web Extra
Extra material supplied by the author
Files in this Data Supplement:
- Data Supplement - Full text of survey
- Data Supplement - Results of multinomial logistic regression
Web Extra
Extra material supplied by the author
Files in this Data Supplement:
- Data Supplement - Full text of survey
- Data Supplement - Results of multinomial logistic regression
Related articles
- Editorial Published: 22 September 2010; BMJ 341 doi:10.1136/bmj.c4777
- Correction Published: 30 September 2010; BMJ 341 doi:10.1136/bmj.c5396
- Education And Debate Published: 27 October 2005; BMJ 331 doi:10.1136/bmj.331.7523.1016
See more
- Communicating risk to patients in the emergency departmentBMJ December 05, 2016, 355 i6437; DOI: https://doi.org/10.1136/bmj.i6437
- Biological treatment is approved for severe eosinophilic asthmaBMJ December 01, 2016, 355 i6472; DOI: https://doi.org/10.1136/bmj.i6472
- Patient care is at risk from lack of new funds in autumn statement, healthcare leaders warnBMJ November 24, 2016, 355 i6356; DOI: https://doi.org/10.1136/bmj.i6356
- Government must be clearer in its claims about NHS funding, says statistics watchdogBMJ November 24, 2016, 355 i6340; DOI: https://doi.org/10.1136/bmj.i6340
- US must address addiction as an illness, not as a moral failing, Surgeon General saysBMJ November 22, 2016, 355 i6265; DOI: https://doi.org/10.1136/bmj.i6265
Cited by...
- Justification of principles for healthcare priority setting: the relevance and roles of empirical studies exploring public values
- Rare diseases in healthcare priority setting: should rarity matter?
- Should rare diseases get special treatment?
- Orphan Drug Expenditures In The United States: A Historical And Prospective Analysis, 2007-18
- The problem of orphan drugs
- Is it time to revisit orphan drug policies?